Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis

BACKGROUND: Many patients with rheumatoid arthritis (RA) require a trial of multiple biologic disease-modifying anti-rheumatic drugs (bDMARDs) to control their disease. With the availability of several bDMARD options, the history of bDMARDs may provide an alternative approach to understanding subphe...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Priyam, Weisenfeld, Dana, Dahal, Kumar, De, Debsurya, Feathers, Vivi, Coblyn, Jonathan S., Weinblatt, Michael E., Shadick, Nancy A., Cai, Tianxi, Liao, Katherine P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236724/
https://www.ncbi.nlm.nih.gov/pubmed/37269020
http://dx.doi.org/10.1186/s13075-023-03072-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236724/
https://www.ncbi.nlm.nih.gov/pubmed/37269020
http://dx.doi.org/10.1186/s13075-023-03072-0

Ejemplares similares